Abstract
While phencyclidine (PCP) and ketamine remain the most well-studied and widely known dissociative drugs, a number of other agents have appeared since the late 1950s and early 1960s, when the pharmacological potential of this class was first realized. For example, hundreds of compounds have been pursued as part of legitimate research efforts to explore these agents. Some of these found their way out of the research labs and onto illicit markets of the 1960s and following decades as PCP analogs. Other “illicit analogs” apparently never appeared in the scientific literature prior to their existence on clandestine markets, thus originating as novel innovations in the minds of clandestine chemists and their colleagues. Like so much else in this world, new technologies changed this dynamic. In the 1990s individuals separated by vast geographical distances could now communicate nearly instantaneously with ease through the Internet. Some individuals used this newly found opportunity to discuss the chemistry and psychoactive effects of dissociative drugs as well as to collaborate on the design and development of novel dissociative compounds. Similar to modern pharmaceutical companies and academic researchers, these seekers tinkered with the structure of their leads pursuing goals such as improved duration of action, analgesic effects, and reduced toxicity. Whether all these goals were achieved for any individual compound remains to be seen, but their creations have been let out of the bag and are now materialized as defined compositions of matter. Moreover, these creations now exist not only in and of themselves but live on further as permutations into various novel analogs and derivatives. In some cases these compounds have made their way to academic labs where potential clinical applications have been identified. These compounds reached wider distribution when other individuals picked up on these discussions and began to market them as “research chemicals” or “legal highs”. The result is a continuously evolving game that is being played between legislatures, law enforcement, and research chemical market players. Two structurally distinct classes that have appeared as dissociative-based new psychoactive substances (NPS) are the 1,2-diarylethylamines and β-keto-arylcyclohexylamines. Examples of the former include diphenidine and various analogs such as fluorolintane and N-ethyl-lanicemine, and examples of the latter are analogs of ketamine such as methoxetamine, deschloroketamine, and 2-fluoro-2-deschloroketamine. The subject of this chapter is the introduction to some of the dissociative NPS from these classes and their known pharmacology that have emerged on the market in recent years.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 2-Cl-DPP (2-Cl-DPH):
-
1-[1-(2-Chlorophenyl)-2-phenylethyl]piperidine
- 2-F-DPPy:
-
1-[1-(2-Fluorophenyl)-2-phenylethyl]pyrrolidine (fluorolintane)
- 2-FDCK:
-
2-(2-Fluorophenyl)-2-(methylamino)cyclohexan-1-one
- 2-MK:
-
2-(2-Methoxyphenyl)-2-(methylamino)cyclohexan-1-one
- 2-MXP:
-
1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine
- 2-oxo-PCA:
-
2-Amino-2-phenylcyclohexan-1-one
- 2-oxo-PCE:
-
2-(Ethylamino)-2-phenylcyclohexan-1-one
- 2-oxo-PCPr:
-
2-Phenyl-2-(propylamino)cyclohexan-1-one
- 2-TFMDCK:
-
2-(Methylamino)-2-[2-(trifluoromethyl)phenyl]cyclohexan-1-one
- 3-MeO-PCP:
-
1-[1-(3-Methoxyphenyl)cyclohexyl]piperidine
- 3-MXP:
-
1-[1-(3-Methoxyphenyl)-2-phenylethyl]piperidine
- 4-MeO-PV8:
-
1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)heptan-1-one
- 4-MeO-PV9:
-
1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one
- 4-MXP:
-
1-[1-(4-Methoxyphenyl)-2-phenylethyl]piperidine
- 5F-ADB:
-
Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate
- 5F-AMB:
-
Methyl (2S)-2-[[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino]-3-methylbutanoate
- 5/6-APB:
-
1-(1-Benzofuran-5-yl)propan-2-amine or 1-(1-benzofuran-6-yl)propan-2-amine
- AB-CHMINACA:
-
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
- AMPA:
-
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- AMT:
-
1-(1H-Indol-3-yl)propan-2-amine (α-methyltryptamine)
- Br-MXE:
-
2-(2-Bromo-5-methoxyphenyl)-2-(ethylamino)cyclohexan-1-one
- DCK:
-
2-(Methylamino)-2-phenylcyclohexan-1-one
- DPE (NEDPA):
-
N-Ethyl-1,2-diphenylethanamine (ephenidine)
- DPiP (NPDPA):
-
N-(1,2-Diphenylethyl)propan-2-amine
- DPP (1,2-DEP):
-
1-(1,2-Diphenylethyl)piperidine (diphenidine)
- DPPy (1,2-DEPy):
-
1-(1,2-Diphenylethyl)pyrrolidine
- FXE:
-
2-(Ethylamino)-2-(3-fluorophenyl)cyclohexan-1-one (fluoroxetamine)
- MK-801:
-
(+)-10,11-Dihydro-5H-5,10-epiminodibenzo[a,d][7]annulene (dizocilpine)
- MXE:
-
2-(Ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine)
- MXM (MMXE):
-
2-(3-Methoxyphenyl)-2-(methylamino)cyclohexan-1-one (methoxmetamine)
- MXP:
-
1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine
- PCA:
-
1-Phenylcyclohexan-1-amine
- PCE:
-
N-Ethyl-1-phenylcyclohexan-1-amine
- PCP:
-
1-(1-Phenylcyclohexyl)piperidine (phencyclidine)
- PV9:
-
1-Phenyl-2-(pyrrolidin-1-yl)octan-1-one
References
Aalto S, Hirvonen J, Kajander J, Scheinin H, Någren K, Vilkman H, Gustafsson L, Syvälahti E, Hietala J (2002) Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacology 164:401–406
Abel KM, Allin MP, Hemsley DR, Geyer MA (2003) Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44:729–737
Adamowicz P, Zuba D (2015) Fatal intoxication with methoxetamine. J Forensic Sci 60(Suppl 1):S264–S268
Adams JD Jr, Baillie TA, Trevor AJ, Castagnoli N Jr (1981) Studies on the biotransformation of ketamine. 1. Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom 8:527–538
Alvarez J-C, Fabresse N, Knapp A, El Hajj Sleiman I, Garnier R, Langrand J (2017) Identification and quantification of diphenidine in hair by LC-MS/MS after single administration. Toxicol Anal Clin 29:64–70
Amphoux A, Vialou V, Drescher E, Brüss M, Mannoury La Cour C, Rochat C, Millan MJ, Giros B, Bönisch H, Gautron S (2006) Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 50:941–952
Anis NA, Berry SC, Burton NR, Lodge D (1983) The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurons by N-methyl-aspartate. Br J Pharmacol 79:565–575
Anonymous (1960) Pharmaceutical compositions and methods for producing phenylcyclohexane compounds. Patent No. GB853775A. Parke Davis, Detroit
Anonymous (2007) Synthese von 2-Methylamino-2-phenylcyclohexanon (MPCH) [7063-30-1]. Last updated: 11 May 2007. http://www.lambdasyn.org/synfiles/mpch.htm. Accessed 26 Mar 2018
Anonymous (2014) The Big & Dandy Methoxmetamine/MXM Thread - V1: Note, this is not MXE! Bluelight. http://www.bluelight.org/vb/threads/732888-The-Big-amp-Dandy-Methoxmetamine-MXM-Thread-V1-Note-this-is-not-MXE! Accessed 24 Apr 2018
Anonymous (2015a) The Big & Dandy 2-Fluoroketamine Thread. Bluelight. http://www.bluelight.org/vb/threads/776753-The-Big-amp-Dandy-2-Fluoroketamine-Thread. Accessed 24 Apr 2018
Anonymous (2015b) Fluorolintane. https://www.ukchemicalresearch.org/Thread-Fluorolintane. Accessed 3 Feb 2018
Anonymous (2017) 2f-DCK vs DCK vs O-PCE, what do you prefer? Reddit. https://www.reddit.com/r/researchchemicals/comments/75iydc/2fdck_vs_dck_vs_opce_what_do_you_prefer/. Accessed 3 Feb 2018
Aspergren BD, Heinzelman RV (1963) Therapeutic 1-(1,2-diphenylethyl) pyrrolidine for the management of depression. Patent No. US3083139. Upjohn Company, Kalamazoo
Aspergren BD, Heinzelman RV (1964) Process for obtaining weight reduction. Patent No. US3134716. Upjohn Company, Kalamazoo
Azzaro AJ, Smith DJ (1977) The inhibitory action of ketamine HCl on [3H]5-hydroxytryptamine accumulation by rat brain synaptosomal-rich fractions: comparison with [3H]catecholamine and [3H]γ-aminobutyric acid uptake. Neuropharmacology 16:349–356
Backberg M, Jonsson KH, Beck O, Helander A (2018) Investigation of drug products received for analysis in the Swedish STRIDA project on new psychoactive substances. Drug Test Anal 10:340–349
Beharry S, Gibbons S (2016) An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 267:25–34
Berger ML, Schweifer A, Rebernik P, Hammerschmidt F (2009) NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds. Bioorg Med Chem 17:3456–3462
Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE (2017) Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.1008.1028
Boateng BO, Fever M, Edwards D, Petersson P, Euerby MR, Sutcliffe OB (2018) Chromatographic retention behaviour, modelling and optimization of a UHPLC-UV separation of the regioisomers of the Novel Psychoactive Substance (NPS) methoxphenidine (MXP). J Pharm Biomed Anal 153:238–247
Botanas CJ, de la Peña JB, Dela Peña IJ, Tampus R, Yoon R, Kim HJ, Lee YS, Jang CG, Cheong JH (2015) Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: evidence of its abuse potential. Pharmacol Biochem Behav 133:31–36
Botanas CJ, Bryan de la Pena J, Custodio RJ, Joy Dela Pena I, Kim M, Woo T, Kim HJ, Kim HI, Chang Cho M, Lee YS, Cheong JH (2017) Methoxetamine produces rapid and sustained antidepressant effects probably via glutamatergic and serotonergic mechanisms. Neuropharmacology 126:121–127
Brunner H, Kagan HB, Kreutzer G (2003) Asymmetric catalysis. Part 153: metal-catalysed enantioselective α-ketol rearrangement. Tetrahedron Asymmetry 14:2177–2187
Caloro M, Calabro G, de Pisa E, Rosini E, Kotzalidis GD, Lonati D, Locatelli CA, Papa P, Schifano F, Girardi P (2018) Combined NMDA inhibitor use in a patient with multisubstance-induced psychotic disorder. J Addict Med. https://doi.org/10.1097/adm.0000000000000390
Campbell KN, Helbing CH, Florkowski MP, Campbell BK (1948) The reaction of Grignard reagents with Schiff bases. J Am Chem Soc 70:3868–3870
Can A, Zanos P, Moaddel R, Kang HJ, Dossou KS, Wainer IW, Cheer JF, Frost DO, Huang XP, Gould TD (2016) Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharmacol Exp Ther 359:159–170
Chambers RA, Bremner JD, Moghaddam B, Southwick SM, Charney DS, Krystal JH (1999) Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin Clin Neuropsychiatry 4:274–281
Champeau W, Eiden C, Gambier J, Peyriere H (2017) Methoxphenidine use disorder: first case notified to the French addictovigilance network. J Clin Psychopharmacol 37:376–377
Chen G (1969) The pharmacology of ketamine. In: Kreuscher H (ed) Ketamine: Bericht über das internationale Symposion am 23. und 24. Februar 1968 in Mainz. Springer, Berlin, Heidelberg, pp 1–11
Chen X, Shu S, Bayliss DA (2009) HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci 29:600–609
Cheng HC, Long JP, Van Orden LS III, Cannon JG, O’Donnell JP (1976) Dopaminergic activity of some apomorphine analogs. Res Commun Chem Pathol Pharmacol 15:89–106
Chiamulera C, Armani F, Mutti A, Fattore L (2016) The ketamine analogue methoxetamine generalizes to ketamine discriminative stimulus in rats. Behav Pharmacol 27:204–210
Chodoff P, Stella JG (1966) Use of CI-581: a phencyclidine derivative for obstetric anesthesia. Anesth Analg 45:527–530
Chretien B, Bourgine J, Hamel Sénécal L, Bretaudeau-Deguigne M, Boels D, Lelong-Boulouard V, Le Boisselier R (2018) Severe serotonin syndrome in an autistic new psychoactive substance user after consumption of pills containing methoxphenidine and α-methyltryptamine. J Clin Psychopharmacol 38:94–96
Christiaen A (1924) Contribution à l’étude de la réaction des organo-magnésiens sur les nitriles. Les nitriles α amines. Bull Soc Chim Belg 33:483–490
Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, Ma WK, Chui KL, Yiu MK, Chan YC, Tse ML, Lau FL (2007) ‘Street ketamine’-associated bladder dysfunction: a report of ten cases. Hong Kong Med J 13:311–313
Cilia J, Hatcher P, Reavill C, Jones DN (2007) (±)Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 21:302–311
Clements JA, Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53:27–30
Cohen ML, Trevor AJ (1974) On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther 189:351–358
Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, Westphal F, Brandt SD, Adejare A (2018) Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues. Drug Test Anal 10:272–283
Coppola M, Mondola R (2012) Methoxetamine: from drug of abuse to rapid-acting antidepressant. Med Hypotheses 79:504–507
Coppola M, Mondola R (2013) Is methoxydine a new rapid acting antidepressant for the treatment of depression in alcoholics? Med Hypotheses 81:10–14
Corazza O, Assi S, Schifano F (2013) From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neurosci Ther 19:454–460
Corssen G, Domino EF (1966) Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45:29–40
Critchlow DG (2006) A case of ketamine dependence with discontinuation symptoms. Addiction 101:1212–1213
Cumming JF (1976) The development of an acute tolerance to ketamine. Anesth Analg 55:788–791
Dargan PI, Tang HC, Liang W, Wood DM, Yew DT (2014) Three months of methoxetamine administration is associated with significant bladder and renal toxicity in mice. Clin Toxicol (Phila) 52:176–180
Davies SN, Alford ST, Coan EJ, Lester RA, Collingridge GL (1988) Ketamine blocks an NMDA receptor-mediated component of synaptic transmission in rat hippocampus in a voltage-dependent manner. Neurosci Lett 92:213–217
Dayton PG, Stiller RL, Cook DR, Perel JM (1983) The binding of ketamine to plasma proteins: emphasis on human plasma. Eur J Clin Pharmacol 24:825–831
de Bruin NM, Ellenbroek BA, Cools AR, Coenen AM, van Luijtelaar EL (1999) Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology 142:9–17
De Luca MT, Badiani A (2011) Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacology 214:549–556
Dodds EC, Lawson W, Williams PC (1944) Morphine-like properties of diphenylethylamine and related compounds. Proc R Soc Lond B Biol Sci 132:119–132
Dodds EC, Lawson W, Simpson SA, Williams PC (1945) Testing diphenylethylamine compounds for analgesic action. J Physiol 104:47–51
Domino EF (2010) Taming the ketamine tiger. Anesthesiology 113:678–684
Domino EF (ed) (2018) Status of ketamine in anesthesiology [reprint from 1990]. NPP Books, Arlington
Domino EF, Chodoff P, Corssen G (1965) Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther 6:279–291
Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333:99–104
EcstasyData.org (2018) https://www.ecstasydata.org/results.php?start=0&search_field=all&s=deschloroketamine. Accessed 2 Apr 2018
Elliott SP, Brandt SD, Freeman S, Archer RP (2013) AMT (3-(2-aminopropyl)indole) and 5-IT (5-(2-aminopropyl)indole): an analytical challenge and implications for forensic analysis. Drug Test Anal 5:196–202
Elliott SP, Brandt SD, Wallach J, Morris H, Kavanagh PV (2015) First reported fatalities associated with the ‘research chemical’ 2-methoxydiphenidine. J Anal Toxicol 39:287–293
Elliott S, Sedefov R, Evans-Brown M (2018) Assessing the toxicological significance of new psychoactive substances in fatalities. Drug Test Anal 10:120–126
EMCDDA (2014) Methoxetamine. Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/775/TDAK14004ENN_480922.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2011) EMCDDA–Europol 2010 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/644/EMCDDA-Europol_Annual_Report_2010A_281336.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2013) New drugs in Europe, 2012. EMCDDA–Europol 2012 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/734/EMCDDA-Europol_2012_Annual_Report_final_439477.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2014) EMCDDA–Europol 2013 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/814/TDAN14001ENN_475519.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2015) EMCDDA–Europol 2014 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2016) EMCDDA–Europol 2015 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/2880/TDAS16001ENN.pdf. Accessed 3 Feb 2018
EMCDDA–Europol (2017) EMCDDA–Europol 2016 annual report on the implementation of Council Decision 2005/387/JHA. In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances. EMCDDA, Lisbon. http://www.emcdda.europa.eu/system/files/publications/4724/TDAN17001ENN_PDFWEB.pdf. Accessed 3 Feb 2018
Energycontrol (2015) Alerta: descloroketamina vendida como ketamina en Barcelona. https://energycontrol.org/analisis-de-sustancias/resultados/alertas/560-alerta-descloroketamina-vendida-como-ketamina-en-barcelona.html. Accessed 3 Feb 2018
Fourcade EW, Lapidus KAB (2016) The basic and clinical pharmacology of ketamine. In: Mathew SJ, Zarate JCA (eds) Ketamine for treatment-resistant depression: the first decade of progress. Springer, Cham, pp 13–29. https://doi.org/10.1007/978-3-319-42925-0_2
Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG (1996) Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 117:689–697
Fray MJ, Bish G, Brown AD, Fish PV, Stobie A, Wakenhut F, Whitlock GA (2006a) N-(1,2-Diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett 16:4345–4348
Fray MJ, Bish G, Fish PV, Stobie A, Wakenhut F, Whitlock GA (2006b) Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett 16:4349–4353
Frison G, Zamengo L, Zancanaro F, Tisato F, Traldi P (2016) Characterization of the designer drug deschloroketamine (2-methylamino-2-phenylcyclohexanone) by gas chromatography/mass spectrometry, liquid chromatography/high-resolution mass spectrometry, multistage mass spectrometry, and nuclear magnetic resonance. Rapid Commun Mass Spectrom 30:151–160
Frohlich J, Van Horn JD (2014) Reviewing the ketamine model for schizophrenia. J Psychopharmacol 28:287–302
Garcia Ruano JL, Parra A, Aleman J, Yuste F, Mastranzo VM (2009) Monoalkylation of primary amines and N-sulfinylamides. Chem Commun 404–406
Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 32:140–144
Gerace E, Bovetto E, Corcia DD, Vincenti M, Salomone A (2017) A case of nonfatal intoxication associated with the recreational use of diphenidine. J Forensic Sci 62:1107–1111
Geyer PM, Hulme MC, Irving JPB, Thompson PD, Ashton RN, Lee RJ, Johnson L, Marron J, Banks CE, Sutcliffe OB (2016) Guilty by dissociation – development of gas chromatography–mass spectrometry (GC-MS) and other rapid screening methods for the analysis of 13 diphenidine-derived new psychoactive substances (NPSs). Anal Bioanal Chem 408:8467–8481
Ghosh P, Bolt AG, Mrongovius RI (1978) 1,2-Diphenylethylamines as potential non-stimulant anorectics. Arzneimittelforschung 28:1561–1564
Goodson LH, Christopher H (1950) Diphenylethylamines.I. The preparation of tertiary amines by the Grignard reaction. J Am Chem Soc 72:358–362
Goodson LH, Wiegand CJW, Splitter JS (1946) Analgesics. I. N-Alkylated 1,2-diphenylethylamines prepared by the Leuckart reaction. J Am Chem Soc 68:2174–2175
Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301–311
Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 53:805–810
Gray NM, Cheng BK (1989) 1,2-Diarylethylamines for treatment of neurotoxic injury. Patent No. EP346791A1. G.D. Searle and Co., Chicago
Grumann C, Vogt S, Huppertz LM, Moosmann B, Franz F, Angerer V, Kramer L, Auwärter V (2016) Drowning due to an intoxication involving the designer drug methoxphenidine – a case report. In: Poster. 54th annual meeting of TIAFT, Brisbane, 28 Aug–1 Sept. https://www.uniklinik-freiburg.de/fileadmin/mediapool/08_institute/rechtsmedizin/pdf/Poster_2016/Grumann_-_Tiaft_2016.pdf. Accessed 3 Feb 2018
Hajkova K, Jurasek B, Sykora D, Palenicek T, Miksatkova P, Kuchar M (2016) Salting-out-assisted liquid-liquid extraction as a suitable approach for determination of methoxetamine in large sets of tissue samples. Anal Bioanal Chem 408:1171–1181
Halberstadt AL, Slepak N, Hyun J, Buell MR, Powell SB (2016) The novel ketamine analog methoxetamine produces dissociative-like behavioral effects in rodents. Psychopharmacology 233:1215–1225
Hansch C, Bjorkroth JP, Leo A (1987) Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 76:663–687
Harvey M, Sleigh J, Voss L, Jose J, Gamage S, Pruijn F, Liyanage S, Denny W (2015) Development of rapidly metabolized and ultra-short-acting ketamine analogs. Anesth Analg 121:925–933
Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O (2015) Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. Forensic Toxicol 33:45–53
Hearne E, Van Hout MC (2016) “Trip-sitting” in the black hole: a netnographic study of dissociation and indigenous harm reduction. J Psychoactive Drugs 48:233–242
Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, Geyer MA, Gouzoulis-Mayfrank E (2007) Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. J Psychopharmacol 21:312–320
Heinzelman RV, Aspergren BD (1953) Compounds containing the pyrrolidine ring. Analogs of sympathomimetic amines. J Am Chem Soc 75:3409–3413
Helander A, Beck O, Bäckberg M (2015) Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clin Toxicol (Phila) 53:446–453
Hesp KD, Stradiotto M (2010) Stereo- and regioselective gold-catalyzed hydroamination of internal alkynes with dialkylamines. J Am Chem Soc 132:18026–18029
Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853–858
Hirota K, Lambert DG (1996) Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth 77:441–444
Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG (1999) Stereoselective interaction of ketamine with recombinant μ, κ, and δ opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology 90:174–182
Ho JH, Dargan PI (2017) Arylcyclohexamines: ketamine, phencyclidine, and analogues. In: Brent J, Burkhart K, Dargan P et al (eds) Critical care toxicology: diagnosis and management of the critically poisoned patient. Springer, Cham, pp 1439–1484
Hofer KE, Grager B, Müller DM, Rauber-Lüthy C, Kupferschmidt H, Rentsch KM, Ceschi A (2012) Ketamine-like effects after recreational use of methoxetamine. Ann Emerg Med 60:97–99
Hofer KE, Degrandi C, Müller DM, Zürrer-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A (2014) Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. Clin Toxicol 52:1288–1291
Holtman JR Jr, Crooks PA, Johnson-Hardy JK, Hojomat M, Kleven M, Wala EP (2008) Effects of norketamine enantiomers in rodent models of persistent pain. Pharmacol Biochem Behav 90:676–685
Hondebrink L, Verboven AHA, Drega WS, Schmeink S, de Groot M, van Kleef R, Wijnolts FMJ, de Groot A, Meulenbelt J, Westerink RHS (2016) Neurotoxicity screening of (illicit) drugs using novel methods for analysis of microelectrode array (MEA) recordings. Neurotoxicology 55:1–9
Hondebrink L, Kasteel EEJ, Tukker AM, Wijnolts FMJ, Verboven AHA, Westerink RHS (2017) Neuropharmacological characterization of the new psychoactive substance methoxetamine. Neuropharmacology 123:1–9
Hondebrink L, Zwartsen A, Westerink RHS (2018) Effect fingerprinting of new psychoactive substances (NPS): what can we learn from in vitro data? Pharmacol Ther 182:193–224
Horsley RR, Lhotkova E, Hajkova K, Jurasek B, Kuchar M, Palenicek T (2016) Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue – behavioural, pharmacokinetic and metabolic studies in the Wistar rat. Brain Res Bull 126:102–110
Hungarian Institute for Forensic Science (2016) Analytical data for Deschloroketamine. Hungarian Institute for Forensic Science. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/Deschloroketamine-ID-HIFS003_rpt.pdf. Accessed 2 Apr 2018
Hurt PH, Ritchie EC (1994) A case of ketamine dependence. Am J Psychiatry 151:779
Hustveit O, Maurset A, Øye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355–359
Jansen KLR (2004) Ketamine: dreams and realities. Multidisciplinary Association for Psychedelic Studies, Sarasota. https://www.maps.org/images/pdf/books/K-DreamsKJansenMAPS.pdf. Accessed 8 Feb 2018
Jones LE, Stewart A, Peters KL, McNaul M, Speers SJ, Fletcher NC, Bell SE (2016) Infrared and Raman screening of seized novel psychoactive substances: a large scale study of >200 samples. Analyst 141:902–909
Jordan S, Chen R, Fernalld R, Johnson J, Regardie K, Kambayashi J, Tadori Y, Kitagawa H, Kikuchi T (2006) In vitro biochemical evidence that the psychotomimetics phencyclidine, ketamine and dizocilpine (MK-801) are inactive at cloned human and rat dopamine D2 receptors. Eur J Pharmacol 540:53–56
Kaizaki-Mitsumoto A, Noguchi N, Yamaguchi S, Odanaka Y, Matsubayashi S, Kumamoto H, Fukuhara K, Funada M, Wada K, Numazawa S (2016) Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market. Forensic Toxicol 34:108–114
Kamenka JM, Geneste P (1981) Synthesis, conformation, and physical properties of phencyclidine and its derivatives. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 47–82
Kang H, Park P, Bortolotto ZA, Brandt SD, Colestock T, Wallach J, Collingridge GL, Lodge D (2017) Ephenidine: a new psychoactive agent with ketamine-like NMDA receptor antagonist properties. Neuropharmacology 112:144–149
Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors-implications for models of schizophrenia. Mol Psychiatry 7:837–844
Kasé Y, Yuizono T, Muto M (1963) Piperidino groups in antitussive activity. J Med Chem 6:118–122
Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK (2013) Ketamine as a new treatment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry 47:710–727
Keiser M, Hasan M, Oswald S (2018) Affinity of ketamine to clinically relevant transporters. Mol Pharm 15:326–331
Kharasch ED, Labroo R (1992) Metabolism of ketamine stereoisomers by human liver microsomes. Anesthesiology 77:1201–1207
Kinoshita H, Tanaka N, Takakura A, Abe H, Kumihashi M, Shibayama T, Jamal M, Ito A, Tsutsui K, Kimura S, Iwase H, Ameno K (2017) An autopsy case of death by combined use of benzodiazepines and diphenidine. Soud Lek 62:40–43
Kjellgren A, Jonsson K (2013) Methoxetamine (MXE) – a phenomenological study of experiences induced by a “legal high” from the internet. J Psychoactive Drugs 45:276–286
Kohrs R, Durieux ME (1998) Ketamine: teaching an old drug new tricks. Anesth Analg 87:1186–1193
Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111–115
Koinig H, Marhofer P, Krenn CG, Klimscha W, Wildling E, Erlacher W, Nikolic A, Turnheim K, Semsroth M (2000) Analgesic effects of caudal and intramuscular S(+)-ketamine in children. Anesthesiology 93:976–980
Kokkinou M, Ashok AH, Howes OD (2018) The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry 23:59–69
Kreuscher H (ed) (1969) Ketamine. Bericht über das internationale Symposion am 23. und 24. Februar 1968 in Mainz. Springer, Berlin
Krupitsky EM, Burakov AM, Romanova TN, Grinenko NI, Grinenko AY, Fletcher J, Petrakis IL, Krystal JH (2001) Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. Neuropsychopharmacology 25:936–947
Krupitsky EM, Burakov AM, Dunaevsky IV, Romanova TN, Slavina TY, Grinenko AY (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39:13–19
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214
Kudo K, Usumoto Y, Kikura-Hanajiri R, Sameshima N, Tsuji A, Ikeda N (2015) A fatal case of poisoning related to new cathinone designer drugs, 4-methoxy PV8, PV9, and 4-methoxy PV9, and a dissociative agent, diphenidine. Leg Med (Tokyo) 17:421–426
Kusano M, Zaitsu K, Taki K, Hisatsune K, Nakajima J, Moriyasu T, Asano T, Hayashi Y, Tsuchihashi H, Ishii A (2017) Fatal intoxication by 5F-ADB and diphenidine: detection, quantification, and investigation of their main metabolic pathways in humans by LC/MS/MS and LC/Q-TOFMS. Drug Test Anal. https://doi.org/10.1002/dta.2215
Laher I, Zhang X, Leung PC, Liang W (2015) Diverse pharmacological properties of ketamine. In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 37–63
Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9–19
Lalonde BR, Wallage HR (2004) Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol 28:71–74
Lam RP, Yip WL, Tsui MS, Ng SW, Ching CK, Mak TW (2016) Severe rhabdomyolysis and acute kidney injury associated with methoxphenidine. Clin Toxicol (Phila) 54:464–465
Lawn W, Borschmann R, Cottrell A, Winstock A (2016) Methoxetamine: prevalence of use in the USA and UK and associated urinary problems. J Subst Use 21:115–120
Le Gall E, Troupel M, Nedelec JY (2006) One-step three-component coupling of aromatic organozinc reagents, secondary amines, and aromatic aldehydes into functionalized diarylmethylamines. Tetrahedron 62:9953–9965
Leander JD, Rathbun RC, Zimmerman DM (1988) Anticonvulsant effects of phencyclidine-like drugs: relation to N-methyl-D-aspartic acid antagonism. Brain Res 454:368–372
Li Q, Man Chan W, Rudd JA, Mei Wang C, Lam PYH, Mun Wai MS, Wood DM, Dargan PI, Yew DT (2013a) Ketamine. In: Dargan PI, Wood DM (eds) Novel psychoactive substances. Academic Press, Boston, pp 285–316
Li Y, Coller JK, Hutchinson MR, Klein K, Zanger UM, Stanley NJ, Abell AD, Somogyi AA (2013b) The CYP2B6*6 allele significantly alters the N-demethylation of ketamine enantiomers in vitro. Drug Metab Dispos 41:1264–1272
Li Y, Jackson KA, Slon B, Hardy JR, Franco M, William L, Poon P, Coller JK, Hutchinson MR, Currow DC, Somogyi AA (2015) CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects. Br J Clin Pharmacol 80:276–284
Licata M, Pierini G, Popoli G (1994) A fatal ketamine poisoning. J Forensic Sci 39:1314–1320
Lilly JC (1996) The scientist. A metaphysical autobiography, 3rd edn. Ronin Publishing, Oakland
Lim DK (2003) Ketamine associated psychedelic effects and dependence. Singap Med J 44:31–34
Lin F, He Y, Zhang L, Zhang M, Zhang Y, Wen C (2015) Assessment of the effect of ketamine on cytochrome P450 isoforms activity in rats by cocktail method. Int J Clin Exp Med 8:4335–4341
Livingston A, Waterman AE (1978) The development of tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol 64:63–69
Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276
Luethi D, Hoener MC, Liechti ME (2018) Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems. Eur J Pharmacol 819:242–247
MacDonald JF, Miljkovic Z, Pennefather P (1987) Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol 58:251–266
Machado-Vieira R, Henter ID, Zarate CA Jr (2017) New targets for rapid antidepressant action. Prog Neurobiol 152:21–37
MacLennan FM (1982) Ketamine tolerance and hallucinations in children. Anaesthesia 37:1214–1215
Maixner J, Jurásek B, Kohout M, Kuchař M, Kačer P (2017) X-ray powder diffraction data for (S)-deschloroketamine hydrochloride, C13H18ClNO. Powder Diffract 32:193–195
Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996) NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301–307
Marcsekova K, Wegener B, Doye S (2005) Ind2TiMe2-catalyzed addition of methyl- and ethylamine to alkynes. Eur J Org Chem 4843–4851
Marietta MP, White PF, Pudwill CR, Way WL, Trevor AJ (1976) Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther 196:536–544
Maskell KF, Bailey ML, Rose SR (2016) Self medication with methoxetamine as an analgesic resulting in significant toxicity. Pain Med 17:1773–1775
Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, Holle SK, Sindic A, Dobrivojevic M, Pavenstädt H, Ciarimboli G (2014) The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch - Eur J Physiol 466:517–527
McCarthy DA (1981) History of the development of cataleptoid anesthetics of the phencyclidine type. In: Domino EF (ed) PCP (phencyclidine): historical and current perspectives. NPP Books, Ann Arbor, pp 17–24
McCarthy DA, Chen G, Kaump DH, Ensor C (1965) General anesthetic and other pharmacological properties of 2-(O-chlorophenyl)-2-methylamino cyclohexanone HCl (CI-581). J Clin Pharmacol 5:21–33
McLaughlin G, Morris N, Kavanagh PV, Power JD, O'Brien J, Talbot B, Elliott SP, Wallach J, Hoang K, Morris H, Brandt SD (2016) Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its meta- and para-substituted isomers. Drug Test Anal 8:98–109
Mealing GA, Lanthorn TH, Small DL, Murray RJ, Mattes KC, Comas TM, Morley P (2001) Structural modifications to an N-methyl-D-aspartate receptor antagonist result in large differences in trapping block. J Pharmacol Exp Ther 297:906–914
Menzies EL, Hudson SC, Dargan PI, Parkin MC, Wood DM, Kicman AT (2014) Characterizing metabolites and potential metabolic pathways for the novel psychoactive substance methoxetamine. Drug Test Anal 6:506–515
Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (2013a) Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem 405:6307–6321
Meyer MR, Orschiedt T, Maurer HH (2013b) Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett 217:137–142
Minakata K, Yamagishi I, Nozawa H, Hasegawa K, Wurita A, Gonmori K, Suzuki M, Watanabe K, Suzuki O (2015) Diphenidine and its metabolites in blood and urine analyzed by MALDI-Q-TOF mass spectrometry. Forensic Toxicol 33:402–408
Mion G, Villevieille T (2013) Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 19:370–380
Moaddel R, Venkata SL, Tanga MJ, Bupp JE, Green CE, Iyer L, Furimsky A, Goldberg ME, Torjman MC, Wainer IW (2010) A parallel chiral-achiral liquid chromatographic method for the determination of the stereoisomers of ketamine and ketamine metabolites in the plasma and urine of patients with complex regional pain syndrome. Talanta 82:1892–1904
Moghimi A, Rahmani S, Zare R, Sadeghzadeh M (2014) Synthesis of 2-(2-fluorophenyl)-2-methylamino-cyclohexanone as a new ketamine derivative. Synth Commun 44:2021–2028
Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M (1997) Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci 42:1183–1185
Moreton JE, Meisch RA, Stark L, Thompson T (1977) Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 203:303–309
Morgan CJ, Curran HV (2012) Ketamine use: a review. Addiction (Abingdon, England) 107:27–38
Morris H (2011) Interview with a ketamine chemist or to be more precise, an arylcyclohexylamine chemist. Vice Mag 18:98–101
Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 6:614–632
Mutti A, Aroni S, Fadda P, Padovani L, Mancini L, Collu R, Muntoni AL, Fattore L, Chiamulera C (2016) The ketamine-like compound methoxetamine substitutes for ketamine in the self-administration paradigm and enhances mesolimbic dopaminergic transmission. Psychopharmacology 233:2241–2251
National Slovenian Forensic Laboratory (2016) Analytical report. Fluorolintane (C18H20FN). 1-(1-(2-fluorophenyl)-2-phenylethyl)pyrrolidine. National Slovenian Forensic Laboratory. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/FLUOROLINTANE-ID-1420-15-report_final.pdf. Accessed 3 Feb 2018
Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118
Ng SH, Tse ML, Ng HW, Lau FL (2010) Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J 16:6–11
Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS (2014) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 54:119–139
Nishimura M, Sato K (1999) Ketamine stereoselectively inhibits rat dopamine transporter. Neurosci Lett 274:131–134
Nishimura M, Sato K, Okada T, Yoshiya I, Schloss P, Shimada S, Tohyama M (1998) Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 88:768–774
Novelli A, Huidobro H (1963) Analogues <<ouverts>> de la papavérine. Activité spasmolytique type papavérine des dériveé de la 1,2(bis-diphényl)-éthylamine. Ann Pharm Fr 21:821–827
Oye I, Hustveit O, Maurset A, Ratti Moberg E, Paulsen O, Skoglund LA (1991) The chiral forms of ketamine as probes for NMDA receptor functions in humans. In: Kameyama T, Nabeshima T, Domino EF (eds) NMDA receptor related agents: biochemistry, pharmacology and behavior. NPP Books, Ann Arbor, pp 381–389
Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213
Pal HR, Berry N, Kumar R, Ray R (2002) Ketamine dependence. Anaesth Intensive Care 30:382–384
Palmer GC, Hutchison JB (1997) Preclinical and clinical aspects of remacemide hydrochloride. In: Herrling PL (ed) Excitatory amino acids. Clinical results with antagonists. Academic Press, San Diego, pp 109–120
Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology 34:1239–1258
Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC (2006) Psychological effects of ketamine in healthy volunteers: phenomenological study. Br J Psychiatry 189:173–179
Preiss D, Tatar A (1995) Verwendung von 2-Methylamino-2-phenylcyclohexanon zur Behandlung von Bakterien-, Pilz-, Virus-, oder Protozoeninfektionen und zur Immunomodulation. Patent No. DE4409671. Berlin
Quirion R, Hammer RP Jr, Herkenham M, Pert CB (1981) Phencyclidine (angel dust)/sigma “opiate” receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci U S A 78:5881–5885
Rao LK, Flaker AM, Friedel CC, Kharasch ED (2016) Role of cytochrome P4502B6 polymorphisms in ketamine metabolism and clearance. Anesthesiology 125:1103–1112
Ribeiro PO, Tome AR, Silva HB, Cunha RA, Antunes LM (2014) Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices. Brain Res 1560:10–17
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2013) The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 8:e59334
Roth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L (2018) Correction: the ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor. PLoS One 13:e0194984
Salat K, Siwek A, Starowicz G, Librowski T, Nowak G, Drabik U, Gajdosz R, Popik P (2015) Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology 99:301–307
Salomone A, Gazzilli G, Di Corcia D, Gerace E, Vincenti M (2016) Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples. Anal Bioanal Chem 408:2035–2042
Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC (2014) Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry 19:978–985
Seeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877–883
Sein Anand J, Wiergowski M, Barwina M, Kaletha K (2012) Accidental intoxication with high dose of methoxetamine (MXE) – a case report. Przegl Lek 69:609–610
Shahani R, Stewart RJ (2008) Reply to letter-to-the-editor, Re: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812, 2007. 71:987
Shahani R, Streutker C, Dickson B, Stewart RJ (2007) Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69:810–812
Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS (2012) Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation. Clin Toxicol (Phila) 50:438–440
Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (2016) In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. J Pharmacol Exp Ther 357:134–144
Slovenian National Forensic Laboratory (2016) Analytical report. Deschloro-N-ethyl-ketamine (C14H19NO). Slovenian National Forensic Laboratory. https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/deschloro-N-ethyl-ketamine-ID-1607-16-rpt060816.pdf. Accessed 3 Feb 2018
Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS (1981) Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 20:391–396
Stevens CL (1962) Aminoketones and methods for their production. Patent no. US3254124A. Parke Davis, Detroit
Stevens CL (1968) α-Hydroxyimines and aminoketones. Patent No. US3394182A. Parke Davis, Detroit
Stevens CL, Elliott RD, Winch BL, Klundt IL (1962) A new rearrangement of α-aminoketones. J Am Chem Soc 84:2272–2274
Stevens CL, Elliott RD, Winch BL (1963) Aminoketone rearrangements. II. The rearrangement of phenyl α-aminoketones. J Am Chem Soc 85:1464–1470
Stevens CL, Klundt IL, Munk ME, Pillai MD (1965a) Amino ketone rearrangements. IV. Thermal rearrangements of α-amino methyl ketones. J Org Chem 30:2967–2972
Stevens CL, Thuillier A, Daniher FA (1965b) Amino ketone rearrangements. III. The rearrangement of α-hydroxy N-phenylimines. J Org Chem 30:2962–2966
Stevens CL, Ash AB, Thuillier A, Amin JH, Balys A, Dennis WE, Dickerson JP, Glinski RP, Hanson HT, Pillai MD, Stoddard JW (1966a) Amino ketone rearrangements. VI. Synthesis of 2-alkylamino-2-phenylcyclohexanones. J Org Chem 31:2593–2601
Stevens CL, Hanson HT, Taylor KG (1966b) Amino ketone rearrangements. V. A kinetic analysis. J Am Chem Soc 88:2769–2774
Stevens CL, Thuillier A, Taylor KG, Daniher FA, Dickerson JP, Hanson HT, Nielsen NA, Tikotkar NA, Weier RM (1966c) Amino ketone rearrangements. VII. Synthesis of 2-methylamino-2-substituted phenylcyclohexanones. J Org Chem 31:2601–2607
Stevens CL, Cahoon JM, Potts TR, Pillai PM (1972) Epoxyamines. III. Synthesis and reactions of 2-(1-aziridinyl)-2-phenyl-3,3-dimethyloxirane and 2-(1-aziridinyl)-2-phenyl-1-oxaspiro[2.4]heptane. J Org Chem 37:3130–3133
Stewart AT Jr, Hauser CR (1955) Synthesis and reactions of α-dialkylaminobenzyl butyl ethers. Interactions with Grignard reagents to form tertiary amines. J Am Chem Soc 77:1098–1103
Storr TM, Quibell R (2009) Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med 23:670–672
Striebel JM, Nelson EE, Kalapatapu RK (2017) “Being with a Buddha”: a case report of methoxetamine use in a United States veteran with PTSD. Case Rep Psychiatry 2017:2319094
Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017) Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546:E1–E3
Svenningsson P, Nomikos GG, Greengard P (2004) Response to comment on “Diverse psychotomimetics act through a common signaling pathway”. Science 305:180
Tainter ML, Luduena FP, Lackey RW, Neuru EN (1943) Actions of a series of diphenyl-ethylamines. J Pharmacol Exp Ther 77:317–323
Tam SW, Zhang AZ (1988) σ and PCP receptors in human frontal cortex membranes. Eur J Pharmacol 154:343–344
Tan S, Chan WM, Wai MS, Hui LK, Hui VW, James AE, Yeung LY, Yew DT (2011) Ketamine effects on the urogenital system – changes in the urinary bladder and sperm motility. Microsc Res Tech 74:1192–1198
Tang HC, Lam PYH, Liang W (2015) In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 227–242
Taschwer M, Hofer MG, Schmid MG (2014) Enantioseparation of benzofurys and other novel psychoactive compounds by CE and sulfobutylether β-cyclodextrin as chiral selector added to the BGE. Electrophoresis 35:2793–2799
Thurkauf A, Monn J, Mattson MV, Jacobson AE, Rice KC (1989) Structural and conformational aspects of the binding of aryl-alkyl amines to the phencyclidine binding site. In: Problems of drug dependence, 1989: Proceedings of the 51st annual scientific meeting, the Committee on Problems of Drug Dependence, Inc. NIDA Research Monograph, vol 95. United States Department of Health and Human Services, National Institute on Drug Abuse, Rockville, pp 51–56
Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY (2009) Ketamine-associated bladder dysfunction. Int J Urol 16:826–829
Tso MM, Blatchford KL, Callado LF, McLaughlin DP, Stamford JA (2004) Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices. Neurochem Int 44:1–7
Turfus SC, Parkin MC, Cowan DA, Halket JM, Smith NW, Braithwaite RA, Elliot SP, Steventon GB, Kicman AT (2009) Use of human microsomes and deuterated substrates: an alternative approach for the identification of novel metabolites of ketamine by mass spectrometry. Drug Metab Dispos 37:1769–1778
UK S.I. No. 239 (2013) The Misuse of Drugs Act 1971 (Amendment) Order 2013 (Statutory Instrument No. 239). http://www.legislation.gov.uk/uksi/2013/239/pdfs/uksi_20130239_en.pdf. Accessed 27 Mar 2018
Valli A, Lonati D, Locatelli CA, Buscaglia E, Tuccio MD, Papa P (2017) Analytically diagnosed intoxication by 2-methoxphenidine and flubromazepam mimicking an ischemic cerebral disease. Clin Toxicol (Phila) 55:611–612
Van Hout MC, Hearne E (2015) “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. J Psychoactive Drugs 47:30–41
Van Hout MC, Hearne E (2017) New psychoactive substances (NPS) on cryptomarket fora: an exploratory study of characteristics of forum activity between NPS buyers and vendors. Int J Drug Policy 40:102–110
Viceland (2017) Hamilton’s pharmacopeia. Season 2. Ketamine; realms and realities. Viceland TV programme. Aired 26 Dec 2017
Vollenweider FX, Leenders KL, Øye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7:25–38
Vutskits L (2018) General anesthetics to treat major depressive disorder: clinical relevance and underlying mechanisms. Anesth Analg 126:208–216
Wallach JV (2014) Structure activity relationship (SAR) studies of arylcyclohexylamines as N-methyl-D-aspartate receptor antagonists. Ph.D. dissertation, University of the Sciences, Philadelphia
Wallach J, Brandt SD (2018) Phencyclidine-based new psychoactive substances. Handb Exp Pharmacol. https://doi.org/10.1007/164_2018_124
Wallach J, Kavanagh PV, McLaughlin G, Morris N, Power JD, Elliott SP, Mercier MS, Lodge D, Morris H, Dempster NM, Brandt SD (2015) Preparation and characterization of the ‘research chemical’ diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. Drug Test Anal 7:358–367
Wallach J, Kang H, Colestock T, Morris H, Bortolotto ZA, Collingridge GL, Lodge D, Halberstadt AL, Brandt SD, Adejare A (2016) Pharmacological investigations of the dissociative ‘legal highs’ diphenidine, methoxphenidine and analogues. PLoS One 11:e0157021
Wang S, Li C (1987) Synthesis of anesthetic compound 2-(O-fluorophenyl)-2-methylamino-cyclohexanone hydrochloride (F-ketamine). Acta Sci Nat Univ Pekin 116–119
Wang Q, Wu Q, Wang J, Chen Y, Zhang G, Chen J, Zhao J, Wu P (2017) Ketamine analog methoxetamine induced inflammation and dysfunction of bladder in rats. Int J Mol Sci 18:E117
Ward J, Rhyee S, Plansky J, Boyer E (2011) Methoxetamine: a novel ketamine analog and growing health-care concern. Clin Toxicol (Phila) 49:874–875
Watterson J (2015) Postmortem toxicology of ketamine. In: Yew DT (ed) Ketamine. Use and abuse. CRC Press, Boca Raton, pp 243–248
Weiner AL, Vieira L, McKay CA, Bayer MJ (2000) Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 18:447–451
Weiß JA, Mohr S, Schmid MG (2015) Indirect chiral separation of new recreational drugs by gas chromatography-mass spectrometry using trifluoroacetyl-L-prolyl chloride as chiral derivatization reagent. Chirality 27:211–215
Westphal F, Junge T, Jacobsen-Bauer A, Rösner P (2010) Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech 77:46–58
WHO (2014) Methoxetamine. Critical review report. Agenda item 4.22. In: Expert Committee on Drug Dependence thirty-sixth meeting, World Health Organization, Geneva, 16–20 June 2014. http://www.who.int/medicines/areas/quality_safety/4_22_review.pdf. Accessed 3 Feb 2018
WHO (2015) MT-45. Critical review report agenda item 5.1. In: Expert Committee on Drug Dependence thirty-seventh meeting, World Health Organization, Geneva, 16–20 Nov 2015. http://www.who.int/medicines/access/controlled-substances/5.1_MT-45_CRev.pdf. Accessed 27 Mar 2018
Wieber J, Gugler R, Hengstmann JH, Dengler HJ (1975) Pharmacokinetics of ketamine in man. Anaesthesist 24:260–263
Wikstrom M, Thelander G, Dahlgren M, Kronstrand R (2013) An accidental fatal intoxication with methoxetamine. J Anal Toxicol 37:43–46
Wink CS, Meyer GM, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (2014) Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MS and LC-HR-MS/MS. Drug Test Anal 6:1038–1048
Wink CSD, Meyer GMJ, Meyer MR, Maurer HH (2015) Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett 238:39–44
Wink CS, Michely JA, Jacobsen-Bauer A, Zapp J, Maurer HH (2016) Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MS(n), and LC-HR-MS(n). Drug Test Anal 8:1005–1014
Winstock AR, Lawn W, Deluca P, Borschmann R (2016) Methoxetamine: an early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample. Drug Alcohol Rev 35:212–217
Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI (2012) Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine. Eur J Clin Pharmacol 68:853–856
Xie L-G, Dixon DJ (2017) Tertiary amine synthesis via reductive coupling of amides with Grignard reagents. Chem Sci 8:7492–7497
Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y, Iga T (2001) Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 29:887–890
Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT (2009) Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett 191:275–278
Yuizono T, Matsuo S, Nakama M, Kase Y, Fujimura H (1970) Chemico-pharmacological studies on antitussives. X. Pharmacological studies on 1,2-diphenyl-1-tert-aminoethane derivatives. Comparison of the optical isomers of 1,2-diphenyl-1-pyrrolidinoethane. Yakugaku Zasshi 90:24–31
Zanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L (2016) Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings. Behav Pharmacol 27:489–496
Zanda MT, Fadda P, Antinori S, Di Chio M, Fratta W, Chiamulera C, Fattore L (2017) Methoxetamine affects brain processing involved in emotional response in rats. Br J Pharmacol 174:3333–3345
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA Jr, Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533:481–486
Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD (2018) Convergent mechanisms underlying rapid antidepressant action. CNS Drugs. https://doi.org/10.1007/s40263-40018-40492-x
Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338
Zarate CA Jr, Mathews D, Ibrahim L, Chaves JF, Marquardt C, Ukoh I, Jolkovsky L, Brutsche NE, Smith MA, Luckenbaugh DA (2013) A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry 74:257–264
Zawilska JB (2014) Methoxetamine – a novel recreational drug with potent hallucinogenic properties. Toxicol Lett 230:402–407
Zeilhofer HU, Swandulla D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 213:155–158
Zhang DX, Levy WB (1992) Ketamine blocks the induction of LTP at the lateral entorhinal cortex-dentate gyrus synapses. Brain Res 593:124–127
Zhang JC, Li SX, Hashimoto K (2014) R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 116:137–141
Zwartsen A, Verboven AHA, van Kleef R, Wijnolts FMJ, Westerink RHS, Hondebrink L (2017) Measuring inhibition of monoamine reuptake transporters by new psychoactive substances (NPS) in real-time using a high-throughput, fluorescence-based assay. Toxicol In Vitro 45:60–71
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Wallach, J., Brandt, S.D. (2018). 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances. In: Maurer, H., Brandt, S. (eds) New Psychoactive Substances . Handbook of Experimental Pharmacology, vol 252. Springer, Cham. https://doi.org/10.1007/164_2018_148
Download citation
DOI: https://doi.org/10.1007/164_2018_148
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-10560-0
Online ISBN: 978-3-030-10561-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)